Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 16/20 | 0.84 |
| ▸ | DRD2 | P14416 | 3/20 | 0.84 |
| ▸ | DRD4 | P21917 | 1/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.68 |
| ▸ | HTR7 | P34969 | 14/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314796 | 0.89 | HTR1A (0.80) | HTR1ADRD2HTR7 | |
| SCHEMBL3318321 | 0.84 | HTR1A (0.81) | HTR1ADRD2DRD4DRD3HTR7 | |
| SCHEMBL26690460 | 0.82 | DRD2 (1.00) | HTR1ADRD2DRD4DRD3HTR7 | |
| SCHEMBL3315701 | 0.82 | DRD2 (1.00) | HTR1ADRD2DRD4DRD3HTR7 | |
| SCHEMBL339483 | 0.81 | DRD2 (0.68) | HTR1ADRD2DRD4DRD3HTR7 | |
| SCHEMBL17274528 | 0.81 | HTR1A (1.00) | HTR1AHTR7 | |
| SCHEMBL26690374 | 0.81 | HTR1A (1.00) | HTR1AHTR7 | |
| SCHEMBL339482 | 0.80 | DRD2 (0.54) | HTR1ADRD2DRD4DRD3HTR7 | |
| Hydrochloric Acid SCHEMBL26612792 | 0.80 | HTR1A (0.97) | HTR1AHTR7 | |
| Hydrochloric Acid SCHEMBL30584617 | 0.80 | HTR1A (0.97) | HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | claimed |
| EP-2142511-A2 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-01-13 | — | — | EP | claimed |
| WO-2008116663-A2 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-10-02 | — | — | WO | claimed |
| US-8236845-B2 | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-08-07 | — | — | US | disclosed |
| US-8236845-B2 | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-08-07 | — | — | US | disclosed |
| US-8236845-B2 | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-08-07 | — | — | US | disclosed |
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| EP-2142511-A2 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008116663-A2 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116663-A2 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | HNMT, NNT, NQO1 | HTR1A 308/4885DRD2 1527/4885DRD4 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.